title: Enhanced drug targeting by attachment of an anti alphav integrin antibody to doxorubicin loaded human serum albumin nanoparticles.
abstract: Specific transport of anti-cancer drugs into tumor cells may result in increased therapeutic efficacy and decreased adverse events. Expression of alphavbeta3 integrin is enhanced in various types of cancer and monoclonal antibodies (mAbs) directed against alphavbeta3 integrins hold promise for anti-cancer therapy. DI17E6 is a monoclonal antibody directed against alphav integrins that inhibits growth of melanomas in vitro and in vivo and inhibits angiogenesis due to interference with alphavbeta3 integrins. Here, DI17E6 was covalently coupled to human serum albumin nanoparticles. Resulting nanoparticles specifically targeted alphavbeta3 integrin positive melanoma cells. Moreover, doxorubicin loaded DI17E6 nanoparticles showed increased cytotoxic activity in alphavbeta3-positive melanoma cells than the free drug. Therefore, DI17E6-coupled human serum albumin nanoparticles represent a potential delivery system for targeted drug transport into alphavbeta3-positive cells.
authors.affiliation: Fraunhofer Institute for Biomedical Engineering, D-66386 St.Ingbert, Germany.
authors.forename: Sylvia
authors.initials: S
authors.lastname: Wagner
authors.forename: Florian
authors.initials: F
authors.lastname: Rothweiler
authors.forename: Marion G
authors.initials: MG
authors.lastname: Anhorn
authors.forename: Daniel
authors.initials: D
authors.lastname: Sauer
authors.forename: Iris
authors.initials: I
authors.lastname: Riemann
authors.forename: Eike C
authors.initials: EC
authors.lastname: Weiss
authors.forename: Alisa
authors.initials: A
authors.lastname: Katsen-Globa
authors.forename: Martin
authors.initials: M
authors.lastname: Michaelis
authors.forename: Jindrich
authors.initials: J
authors.lastname: Cinatl
authors.forename: Daniel
authors.initials: D
authors.lastname: Schwartz
authors.forename: Jörg
authors.initials: J
authors.lastname: Kreuter
authors.forename: Hagen
authors.initials: H
authors.lastname: von Briesen
authors.forename: Klaus
authors.initials: K
authors.lastname: Langer
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000737:chemistry* / Q000378:metabolism; D000970:Antineoplastic Agents / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use; D001672:Biocompatible Materials / Q000737:chemistry / Q000378:metabolism; D002448:Cell Adhesion; D045744:Cell Line, Tumor; D002470:Cell Survival; D004317:Doxorubicin / Q000737:chemistry* / Q000378:metabolism; D004337:Drug Carriers / Q000737:chemistry* / Q000378:metabolism; D016503:Drug Delivery Systems; D006801:Humans; D039564:Integrin alphaV / Q000276:immunology*; D008422:Materials Testing; D053758:Nanoparticles; D009369:Neoplasms / Q000188:drug therapy; D012709:Serum Albumin / Q000737:chemistry* / Q000378:metabolism; D013438:Sulfhydryl Compounds / Q000737:chemistry
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001672:Biocompatible Materials; D004337:Drug Carriers; D039564:Integrin alphaV; D012709:Serum Albumin; D013438:Sulfhydryl Compounds; C000592911:Abituzumab; D004317:Doxorubicin